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Purpose: Acquired nystagmus, a highly symptomatic consequence of damage to the substrates of oculomotor
control, often is resistant to pharmacotherapy. Although heterogeneous in its neural cause, its expression is uniﬁed
at the effectordthe eye muscles themselvesdwhere physical damping of the oscillation offers an alternative
approach. Because direct surgical ﬁxation would immobilize the globe, action at a distance is required to damp the
oscillation at the point of ﬁxation, allowing unhindered gaze shifts at other times. Implementing this idea magnet-
ically, herein we describe the successful implantation of a novel magnetic oculomotor prosthesis in a patient.
Design: Case report of a pilot, experimental intervention.
Participant: A 49-year-old man with longstanding, medication-resistant, upbeat nystagmus resulting from a
paraneoplastic syndrome caused by stage 2A, grade I, nodular sclerosing Hodgkin’s lymphoma.
Methods: We designed a 2-part, titanium-encased, rare-earth magnet oculomotor prosthesis, powered to
damp nystagmuswithout interferingwith the larger forces involved in saccades. Its damping effects were conﬁrmed
when applied externally. We proceeded to implant the device in the patient, comparing visual functions and high-
resolution oculography before and after implantation andmonitoring the patient for more than 4 years after surgery.
Main Outcome Measures: We recorded Snellen visual acuity before and after intervention, as well as the
amplitude, drift velocity, frequency, and intensity of the nystagmus in each eye.
Results: The patient reported a clinically signiﬁcant improvement of 1 line of Snellen acuity (from 6/9 bilat-
erally to 6/6 on the left and 6/5e2 on the right), reﬂecting an objectively measured reduction in the amplitude, drift
velocity, frequency, and intensity of the nystagmus. These improvements were maintained throughout a follow-up
of 4 years and enabled him to return to paid employment.
Conclusions: Thisworkopensanewﬁeldof implantable therapeuticdevicesdoculomotorprostheticsddesigned
tomodify eyemovementsdynamically byphysicalmeans in caseswhereapurely neural approach is ineffective.Applied
to acquired nystagmus refractory to all other interventions, it is shown successfully to damp pathologic eye oscillations
while allowing normal saccadic shifts of gaze. Ophthalmology 2017;-:1e9 ª 2017 by the American Academy of
Ophthalmology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Supplemental material available at www.aaojournal.org.An estimated 0.24% of the population has persistent
nystagmus, an abnormal rhythmic oscillation of the eyes
typically of neural origin.1 When acquired later in life,
nystagmus often is associated with oscillopsia, a
distressing perception of constant movement of the visual
scene that is both intrinsically disabling and a cause of
reduced visual acuity.2 The impact of nystagmus on life is
substantial, and visual functioning scores typically are
lower than those for better-known visual impairments such
as age-related macular degeneration.3 Although many drugs
have been evaluated, no generally effective pharmacologic
treatment exists.4 Given the heterogeneity of the
underlying physiologic dysfunction, no single agent
conceivably could target what is likely to be a complex
multiplicity of potential neural loci, and thus the historical
wide individual variability in the response to
pharmacotherapy is likely to continue.ª 2017 by the American Academy of Ophthalmology
This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/). Published by Elsevier Inc.Although nystagmus has many different origins within
the central nervous system, all converge on a single target:
the extraocular muscles that move the globe itself. There-
fore, an intervention that attenuates the action of oculomotor
muscles could offer an effective treatment for nystagmus,
regardless of the cause. Unfortunately, although strabismus
surgery may sometimes improve the location of the point of
gaze where the nystagmus is less pronounceddknown as a
null pointdcomplete immobilization of the eyes generally
is unhelpful because it blocks any ability to shift gaze; this
type of intervention generally is restricted only to cases of
third-nerve palsy with very large angle deviations refractory
to other surgical approaches.5
The ideal solution is to attenuate the oscillation of the
eyes when the patient is ﬁxating a target, while still
permitting saccadic movements necessary to reﬁxate.
Because saccadic forces are substantially greater than the1http://dx.doi.org/10.1016/j.ophtha.2017.05.028
ISSN 0161-6420/17
Ophthalmology Volume -, Number -, Month 2017forces generating the pathologic drift that triggers each
nystagmic jerk,6 it follows that an intermediate force could
damp nystagmus without preventing saccades. Crucially,
such force needs to be delivered remotely, without direct
physical contact that otherwise would lead to
postoperative ﬁbrosis and loss of ocular motility.
Currently, the only practical means of achieving action at
a distance is magnetic, permanent, rare earth magnets
having sufﬁcient magnetic ﬂux density while remaining of
implantable size.
We therefore conceived a permanent magnetic implant
with a pair of interacting elements: an orbital part ﬁxed to
the orbital wall and an ocular part tethered to an extraocular
muscle. The implant location is determined by the plane of
the dominant drift component of the nystagmusdthe orbital
ﬂoor for vertical nystagmus and the lateral wall for
horizontaldwith the ocular part sited within the Tenon’s
sheath of the relevant muscle, thereby maintaining a mobile
tissue boundary between the 2 elements. The magnetic force
thus damps ocular oscillation, while leaving a full range of
movement and essentially normal saccadic gaze shifts.
Herein we describe the design, implantation, and evaluation
of a prototype device in 1 patient with highly symptomatic,
treatment-resistant upbeat nystagmus and report the clinical
observations, including those from a more than 4-year
follow-up period after surgery.Methods
Patient
The patient, a right-handed man in full-time employment as a
driver of commercial heavy goods vehicles, was referred to the
neuro-ophthalmology clinic at 49 years of age for progressive
unsteadiness, slurred speech, vertigo, and variable diplopia
evolving over 2 years. At presentation, there was upbeat nystagmus
on lateral gaze, but not in the primary position, and broken pursuit.
Horizontal diplopia was present just for distance causing a
concomitant distance right esotropia of 8 prism diopters (PD) base
out. His Snellen visual acuity was 6/5þ3 in the right eye and 6/5e3
in the left. Other than mild dysarthria, the rest of the neurologic
examination was unremarkable.
Routine investigations revealed a mediastinal mass subse-
quently identiﬁed as stage 2A, grade I, nodular sclerosing Hodg-
kin’s lymphoma, for which he received 3 courses of standard
doxorubicin, bleomycin, vinblastine, and dacarbazine chemo-
therapy and involved ﬁeld radiotherapy of 35 Gy in 20 fractions,
leaving him in sustained, complete remission. There were other-
wise no biochemical, hematologic, serologic, or cerebrospinal ﬂuid
abnormalities. Magnetic resonance imaging of the brain showed
only mild cerebellar atrophy.
Despite successful tumor treatment, his symptoms progressed
to include distressing oscillopsia. Repeat examination now
showed nystagmus in the primary gaze with no null point, and his
visual acuity had dropped to 6/9 bilaterally. The angle of squint
increased and stabilized at 30/35 PD base out, near and distance.
Ocular motility revealed mild lateral gaze defects (0.5) in both
eyes, 0.5 right inferior rectus underaction, and an A pattern.
This symptomatic progression contributed to his loss of
employment.
A diagnosis of paraneoplastic cerebellar syndrome was made.
There was no response to corticosteroid immunomodulation or to a2course of intravenous immunoglobulins. The clinical picture
remained static until the present intervention, 7 years after the
original diagnosis.
In the intervening years, many pharmacologic agents for
symptomatic treatment of the nystagmus were tried without
success, including benzodiazepines, carbamazepine, valproate,
levetiracetam, gabapentin, acetazolamide, phenytoin, memantine,
baclofen, 3-4 diaminopyridine, and 4-aminopyridine.
Faced with symptoms he found profoundly debilitating, the
patient asked us to consider novel experimental approaches. This
led us to recollect an informal report from a Brazilian ophthal-
mologist, Harley Bicas, about the successful use of implantable
magnets in nystagmus (theoretically elaborated by him after our
intervention was concluded7). The patient’s request prompted the
research project described in this study. Informed consent was
obtained following procedures approved by an ethics committee
with speciﬁc expertise in handling device studies (London-
Dulwich NRES Committee). All research adhered to the tenets
of the Declaration of Helsinki.
Implant Design
We designed a 2-part rare-earth magnetic implant consisting of a
small cylindrical ocular part designed to be sutured to an extra-
ocular muscle near its insertion and within the tendinous sheath and
a larger cylindrical orbital part designed to be ﬁxed to the orbital
wall. The thickness of the orbital magnet was conceived to be
variable, guided by the external testing of prototypes of the same
diameter, but of different lengths, externally before implantation
(see below). The ocular magnet was designed to be made of sin-
tered samariumecobalt material, and the orbital magnet was
designed to be made of sintered neodymiumeironeboron, with the
magnetic axis in both being aligned to the cylindrical axis. The
ocular magnet was a cylinder 3 mm in diameter and 1 mm in
length, and the orbital magnet was a cylinder 3.73 mm in diameter
and 2 mm in length. Because permanent magnetic materials are
biologically reactive, each part was encased in grade 2 titanium,
with laser welded joints, and the titanium cases included small
ﬂanges to facilitate suturing (for the ocular part) or gluing (for the
orbital part). The ﬁnal design was custom manufactured by Magnet
Sales & Service Ltd (Swindon, United Kingdom). Note that the
magnetic materials exhibit sufﬁcient temperature stability to allow
standard sterilization techniques to be applied.
Extraoperative Procedures
Oculometrics. The capacity to maintain ﬁxation at cardinal
positions of the gaze was assessed with the aid of high-resolution
video-based eye tracking. A single, white, square-shaped stimulus
subtending 0.5 of visual angle was displayed on a black back-
ground on a 21-inch cathode ray tube monitor (1024  768 pixels;
refresh rate, 140 Hz) at a viewing distance of 60 cm. Eye position
was monitored at 1000 Hz (EyeLink 1000; SR Research, Ottawa,
Canada). Both pupil and corneal reﬂections were used (dual
tracking mode), and eye position calibration was performed using
EyeLink’s standard 9-point calibration screen.
The patient followed the ﬁxation stimulus sequentially to each
of 9 positions on the screen in a randomized predetermined order
while keeping his head ﬁxed with the aid of a chinrest and headrest.
Each ﬁxation point was maintained for 30 seconds. The 9 positions
fell on an invisible regular rectilinear grid subtending 30 of visual
angle in each dimension. He was encouraged to maintain ﬁxation
as accurately as he could. No optical correction was used. Data for
each eye were acquired during both binocular and monocular
viewing; binocular data are reported as closest to real-life experi-
ence. Both the raw position data with respect to time and saccades
Figure 1. Photographs of right eye obtained during surgery showing:
(A) the exposed inferior rectus muscle (long arrow) with a squint hook
retracting the muscle at its insertion to the globe (short arrow) and (B) the
positioned orbital magnet ﬁxed to the orbital ﬂoor (long arrow) and the
lower lid being retracted with a Desmarres retractor (short arrow).
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EyeLink criteria for a saccade were acceleration of 1000 per
second squared, velocity of 30 per second, and amplitude of more
than 0.1. This experimental set up was replicated identically for
both preoperative and postoperative testing.
Oculometric data were analyzed independently for each
recording session, eye, and gaze location using custom Matlab
scripts (Mathworks, Natick, MA). For each rapid eye movement
detected by EyeLink as a saccade according to the above criteria,
we calculated the displacement amplitude (in degrees) and the
slow-phase drift velocity in the interval 100 to 20 ms preceding it
(in degrees per second). The interval between each rapid movement
gave us a measure of instantaneous frequency (in hertz), and the
product of frequency and amplitude gave us the derived metric of
intensity (in degrees hertz), which has been used as a real-life
informative measure of the severity of nystagmus.8 Because each
of these parameters can be derived for every nystagmic jerk, we
were able to perform statistical comparisons, separately for each
parameter, across each recording session, each eye, and each of
the 9 gaze locations. We used a 2-sample Kolmogorov-Smirnov
test for these comparisons, with asymptotic calculation of signiﬁ-
cance values. The medians of the distributions for each metric,
session, eye, and gaze location were presented as spider plots,
together with standard errors of the medians, with the asymptotic
signiﬁcance values of the relevant statistical comparison presented
on each axis.
Although reasonable calibration was achieved, for robustness
we performed an additional analysis of the amplitude and drift
velocity parameters where the eye position data were subjected ﬁrst
to an afﬁne transform, derived by minimizing the squared error
over possible transformation matrices, that takes into account
translational, rotational, skew, and scaling differences between
calibrated and actual calibration positions. Because such off-line
calibration correction inevitably assumes a linear interpolation of
error across locations, unjustiﬁably propagating errors across the
ﬁeld of view, we present this analysis in addition to the conven-
tionally calibrated data.
For illustrating the effect of the intervention on ﬁxation sta-
bility, we estimated the spatial probability densities of the raw
ﬁxation position data (sampled at 1 ms) for the most stable location
(lower middle) in each eye, both before and after surgery. The
estimates were calculated using bivariate adaptive kernel density
estimation.9 These plots index the degree of stability of the gaze by
the width of the distribution: the narrower, the more stable the
gaze. Note that no inferential comparison was performed here or
was intended.
External Implant Testing. To conﬁrm that the force exerted by
the implant would be sufﬁcient to attenuate the patient’s nystagmus
without impeding saccades, we created a mechanical platform for
applying the same force externally. Drawing on an established
approach for nontraumatic, noninvasive application of forces to the
eye,10 we adapted a table-mounted conventional slit-lamp micro-
scope (SM-2; Takagi Seiko Co, Ltd., Iwafune, Nakano-shi,
Nagano-ken, Japan), attaching to the headrest a custom-made ste-
reotactic frame (Integrated Technologies Ltd, Ashford, Kent,
United Kingdom) that allowed us precisely to position different-
sized prototypes of the orbital part of the implant in relation to
the tested eye using an adjustable cylindrical sliding arm ﬁxed to
the frame. A set of custom-made, fenestrated, polymethyl meth-
acrylate scleral contact lenses, molded to the patient’s eyes (made
by Ken Pullum; http://www.kenpullum.co.uk/) were adapted to
allow cyanoacrylate adhesive ﬁxation of a single prototype of the
ocular part of the implant on the external apex. Adhesive also was
applied to the magnet surface to simulate the spacing of intervening
tissue between the 2 parts of the implant. Because there is lessscope for variation in the size of the ocular magnet, this was kept as
a single, ﬁxed disc of 3 mm in diameter, 1 mm in thickness
(Samariumecobalt material). Tygon tubing (1.6 mm inner diam-
eter, 3.2 mm outer diameter; Cole-Parmer Instrument Co Ltd),
attached to the fenestration of each lens with cyanoacrylate adhe-
sive, was linked to a manually operated 10-ml syringe through
which a low-pressure suction adherence to the ocular surface could
be maintained. Any force applied to the contact lens thus could be
transmitted securely to the eye. The slit-lamp microscope allowed
close ocular monitoring before, during, and after the procedure.3
Figure 2. A, Orbital computer tomographic image showing the position of the right implant in the coronal plane. Note that the space between the
2 components is not visible because of artefact. B, Lateral plain radiograph showing the position of the right implant in the sagittal plane in 3 positions of
gaze: neutral, upgaze, and downgaze. Note the movement of the eye component relative to the orbital component.
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headrest. Only the right eye was tested, because it was
assumed any interocular difference in forces was likely to be
both trivial and within the margin of error of the test procedure.
One operator (P.N.) observed the right eye through the slit-lamp
microscope and the second operator (C.K.) inserted the scleral
contact lens with premounted magnet onto the patient’s eye. The
sliding arm, bearing an orbital part prototype at its tip, then was
advanced until the 2 magnets were just in contact. At this point,
suction was applied, transiently ﬁxing the scleral contact lens to4the eye for approximately 30 seconds, while the degree of
ocular stabilization was observed through the slit-lamp micro-
scope; during this period, the patient was asked to make a few
saccades to check that he was able to overcome the magnetic
force. The stabilization was repeated 3 times. A cylindrical N40
neodymiumeironeboron magnet of 4 mm in diameter and 2
mm in length was found both to stabilize the nystagmus and
also to allow saccadic reﬁxations. The ocular surface was
inspected after the procedure to ensure that no abrasion had
occurred.
Figure 3. Example oculomotor trace before (Pre) and after (Post) surgery. A sample of eye movement amplitude during attempted ﬁxation, indexed along
the vertical displacement and plotted before (black) and after (red) bilateral implantation. The trace is derived from the left eye in a position of moderate
damping: 15 downgaze in the vertical midline. Note the obvious fall in amplitude.
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Magnet implantation was performed under general anesthesia, with
an interval of 4 months between the ﬁrst (right) and second (left)
orbits. The lower eyelid was retracted with 2 sutures of 2-0 silk,
and the conjunctiva opened along its length in the depth of the
fornix. With the conjunctiva placed on traction with 2 sutures of
6-0 silk, the anterior portion of the inferior rectus muscle was
exposed by blunt dissection, and the Tenon’s sheath was opened
anteriorly and brushed backward to expose the anterior 15 mm of
the inferior rectus. The smaller magnet (the ocular component) was
sutured to the undersurface of the inferior rectus, centered
approximately 10 mm behind the muscle insertion with 3 sutures of
6-0 polyglactin; the Tenon’s sheath then was drawn forward over
the magnet and sutured anteriorly with the same suture (Fig 1A).
The orbital ﬂoor was exposed through the same incision, the
larger magnet was placed alongside the ocular magnet, and the
eye was aligned to primary position, allowing an estimate for the
optimal position of the orbital magnet; this position was
maintained while medical-grade cyanoacrylate glue was run into
the gap between the orbital ﬂoor and magnet base (Fig 1B). The
conjunctiva was closed with 1 rapidly absorbing 8-0 polyglactin
suture, chloramphenicol ointment was instilled into the
conjunctival sac, and the eye was padded for 48 hours. The
patient was discharged home with a rapidly reducing course of
oral corticosteroids, oral antibiotics, and topical chloramphenicol.
Postimplantation Surgical Procedures
The patient continued to experience problematic diplopia, as not
uncommonly observed in paraneoplastic cerebellar disorders,11,12
with a moderate A-pattern esotropia. Seven months after implant
surgery, the right esotropia reduced to 18 PD base out with 5 D
hypertropia. An A pattern was still apparent, with mild bilateral
lateral gaze defects (0.5) and bilateral upgaze defect (1). He
underwent 3 strabismus procedures at 7, 20, and 25 months after
orbital implantation: right eye adjustable medial rectus recess
(inferior transposition) and lateral rectus resect (inferior trans-
position) for vertical element; bilateral superior oblique tenoto-
mies; and left eye adjustable medial rectus recess and lateral rectus
resect (no transposition), respectively. In the interval between the
ﬁrst 2 strabismus procedures, his symptoms were managed with
Fresnel prisms, Bangerter occlusion foil, and botulinum toxin in-
jections to both medial and inferior rectus muscles. After the third
strabismus operation, the patient has maintained a useful central
area of binocular single vision with regular botulinum toxin in-
jections to the medial rectus muscle to manage his residual 16-PD
base-out esotropia, because he remains intolerant of a prism of
more than 12 D base out.Imaging
The orbit was imaged after the ﬁrst implantation (Fig 2A); lateral
plain radiographs in upgaze and downgaze also were obtained to
show the relative excursion of the implant parts (Fig 2B).
Role of the Funding Source
Apart from funding the project and monitoring its progress, the
funder’s role was limited to reviewing a draft of the article before
submission.
Results
After recovery from surgery, the patient reported that the oscil-
lopsia had improved, especially on downgaze, although this was
accompanied by a greater perception of diplopia, which had been a
prominent symptom before oscillopsia developed. His visual acuity
improved from 6/9 bilaterally to 6/6 on the left and 6/5e2 on the
right, in the direction of optimally stabilized gaze; these parameters
have remained stable over 4 years of follow-up.
The relative position of the 2 parts varied with the gaze,
revealing the mechanism producing a gaze-dependent damping
effect. Lateral radiographs show magnetic separation to be greatest
on downgaze and accompanied by a tilt of the ocular part, causing
the axis of maximum magnetic force and the axis of eye oscillation
to coincide more closely. Therefore, the vector component
contributing to the damping is increased compared with other
positions of gaze (Fig 2B).
A quantitative assessment was carried out 8 days after the second
implantation, and inspection of the raw traces showed an evident
change from the preoperative state (Fig 3), this being reﬂected in the
objective metrics of oculomotor behavior (Figs 4 and 5). The metrics
considered most closely related to symptomsdamplitude and
intensitydimproved signiﬁcantly in both eyes for most positions
of the gaze, but especially on downgaze. The overall picture
remained substantially unchanged with off-line recalibrated data
(Table S1, available at www.aaojournal.org).
To illustrate improved ﬁxation, we further estimated the
probabilityedensity functions describing the variability in ﬁxation
position for the gaze locations with greatest damping. The resultant
2-dimensional surface plots (Fig 6) deﬁne the degree of ﬁxation
stability by the width of the visualized peak: the narrower the
peak, the more stable the ﬁxation. These subjective and objective
improvements in vision were paralleled by real-life impact: the
patient was able to return to part-time work, although not as a
driver, and daily functions such as reading and watching television
improved substantially. Nonetheless, he remains symptomatic from
a relatively small degree of diplopia, correction of which is5
Figure 4. Spider plots of the nystagmus parameters in the left eye before and after bilateral surgery. Each of the panels corresponding to the 9 positions of
evaluated gaze shows the median amplitude, frequency, presaccadic velocity, and intensity of the nystagmus in the left eye at that position before (Pre; solid
black line) and after (Post; solid red line) bilateral surgery. The dotted lines show 1 standard error of the median. The signiﬁcance (P) values at each corner are
derived asymptotically from a 2-sample Kolmogorov-Smirnov test for a difference in the paired distributions. The axes ranges are set to the maximum across
eyes and conditions. On each of the 4 axes, a smaller value corresponds to a decrease in the corresponding nystagmus parameter: where the resultant
diamond shape is smaller after implantation, the nystagmus is improved objectively. Note that there is generally a marked improvement in the parameters,
especially in the downgaze positions as observed clinically.
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Figure 5. Spider plots of the nystagmus parameters in the right eye before and after bilateral surgery. Each of the panels corresponding to the 9 positions of
evaluated gaze shows the median amplitude, frequency, presaccadic velocity, and intensity of the nystagmus in the right eye at that position before (solid black
line) and after (solid red line) bilateral surgery. The dotted lines show 1 standard error of the median. The signiﬁcance (P) values at each corner are derived
asymptotically from a 2-sample Kolmogorov-Smirnov test for a difference in the paired distributions. The axes ranges are set to the maximum across eyes and
conditions. On each of the 4 axes, a smaller value corresponds to a decrease in the corresponding nystagmus parameter: where the resultant diamond shape is
smaller after implantation, the nystagmus is improved objectively. Note that there is generally a marked improvement in the parameters, especially in the
downgaze positions as observed clinically.
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Figure 6. Visualization of the impact on ﬁxation of the implantation. Plotted for each eye before and after surgery are ﬁts of the spatial probability density
functions of the point of gaze during ﬁxation at the maximally damped position for each eye. The spatial scale is in degrees, identical in the x- and y-planes.
The narrower the distribution is, the more stable the ﬁxation is. Note the apparent improvement in the stability of ﬁxation reﬂecting the change in
nystagmus parameters shown in Figures 3 and 4.
Ophthalmology Volume -, Number -, Month 2017complicated by the fusional deﬁcit (Fig S7, available at
www.aaojournal.org). Importantly, there has been no discernible
impact on shifts of gaze or on functional range of eye movement
over 4 years.
Discussion
This is the ﬁrst description of the successful treatment of an
oculomotor disorder with an implanted prosthesis, address-
ing a functional abnormality of neural origin by remote
physical means. It opens the way to other applications where
oculomotor dysfunction cannot be corrected by altering
neural function and where the desired effect is beyond the
reach of conventional surgical methods. Although a passive
device was used, even more precise modiﬁcation may be
achievable with the use of active devices that are able to
adapt dynamically and responsively to the host. Here we8discuss the possibilities and limitations of the approach in
relation to the treatment of nystagmus.
Although we remain far from a mechanistic explanation of
nystagmus, the diversity of causative pathologic features
suggests a mechanistic heterogeneity that is unlikely to be
addressable by any simple manoeuvre at the neural level.
Indeed, this is reﬂected in the clinical experience of the agents
currently in use, where side effects may be as prominent as
anydgenerally limiteddtherapeutic beneﬁts. By focusing on
the effectordthe eye muscles themselvesdthe therapeutic
approach can be insulated from its neural causation: What
matters is the movement of the eye, not how it is generated.
Because the pathologic component of nystagmus is the
slow drift that the fast phase corrects subsequently, adequate
damping can be produced by a force substantially smaller
than that involved in the generation even of relatively small
saccades. This minimizes the risk of immobilizing the eye
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forward to insert. By inserting the ocular part inside Tenon’s
sheath, thereby maintaining a lubricated sliding surface
between the parts of the implant, ﬁbrosis that otherwise
could restrict eye movement probably can be avoided.
The procedure is relatively straightforward, does not
require intraoperative imaging, and relies on no specialist
equipment other than nonmagnetic surgical instruments. The
implant itself is relatively inexpensive tomanufacture, and the
use of titaniumdthe only structural material in contact with
the bodydis well established in the orbit. The patient made a
rapid recovery from both implantations, with slightly more
inﬂammation after the ﬁrst surgery when postoperative ste-
roids were not administered. Both subjectively and objec-
tively, the patient’s visual function improved, and this was
reﬂected in real-life changes in his capacity for employment.
However, the ocular stabilization did reveal problems with
binocular fusion that had been present before surgery.
There are, however, some limitations that need careful
consideration. Whether the beneﬁts can be extended to other
types of nystagmus remains to be seen. Because the
presence of ferromagnetic materials is an absolute contra-
indication to magnetic resonance imaging, patients with
progressive or recurrent neurologic illness requiring
magnetic resonance surveillance are not candidates for such
surgery. It is also worth noting that the strongest effect
observed in our patient was the creation of a downgaze null
point, and it may be the case that only patients without a
natural null point are likely to experience a similar func-
tional beneﬁt. Finally, any changes of extraocular muscle
function risk creating or exacerbating binocular diplopia.
Owing to cerebellar syndrome, there was pre-existing
diplopia resulting from a fusional defect, and this became
more evident and symptomatic after surgery. Where morethan 1 set of implants are used or where the implant is in the
lateral plane, such effects may be less pronounced.References
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